Investors
Our investor proposition
GSK is a science-led global healthcare company that aims to deliver growth and improving returns to shareholders through the development of innovative pharmaceutical, vaccine and consumer healthcare products.
Key information
2020 Second quarter results announcement
We announced our second quarter results for the period ended 30 June 2020 on Wednesday 29 July.
Latest information
Press releases for media
- FDA approves GSK’s BLENREP (belantamab mafodotin-blmf) for the treatment of patients with relapsed or refractory multiple myeloma
- Sanofi and GSK in advanced discussions with European Union to supply up to 300 million doses of COVID-19 vaccine
- Sanofi and GSK selected for Operation Warp Speed to supply United States Government with 100 million doses of COVID-19 vaccine
- GSK delivers Q2 sales of £7.6 billion -2% AER, -3% CER (Pro-forma -10% CER*)
Annual Report 2019
We published our Annual Report 2019 on 04 March 2020. View the summary and download the full report or individual sections.